<DOC>
	<DOCNO>NCT01985087</DOCNO>
	<brief_summary>In study propose determine outcomes patient age 70 older treat radiation 2 week give temozolomide 75 mg/m2 daily radiotherapy post radiation treatment 150 mg/m2 - 200 mg /m2 6 cycle disease progress .</brief_summary>
	<brief_title>A Study Using Radiation Therapy Temozolomide Treat Glioblastoma Patients Over 70</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Participants must histologically confirm glioblastoma/gliosarcoma . 2 . Tumor o6methylguanineDNAmethyltransferase promoter methylation status must determine 3 . Participants must prior therapy glioblastoma multiforme include radiation chemotherapy . 4 . Participants must &gt; 70 year age . 5 . Participants must life expectancy great 6 month . 6 . Karnofsky performance status &gt; 60 ( ECOG &lt; 2 ) . 7 . Patients must normal organ marrow function Leukocytes &gt; 3,000/microliter Absolute neutrophil count &gt; 1,500/microliter Platelets &gt; 100,000/microliter Total bilirubin within normal institutional limit 12 aspartate aminotransferase test ( SGOT ) /alanine aminotransferase test ( SGPT ) &lt; 2.5 X institutional upper limit normal Creatinine within normal institutional limit creatinine clearance &gt; 60 mL/min/1.73 m2 subject creatinine level institutional normal 8 . Ability understand willingness sign write informed consent document . 1 . Participants may receive study agent . 2 . Participants may chemotherapy wafer placement surgery . 3 . History allergic reaction attribute compound similar chemical biologic composition temozolomide . 4 . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 5 . Individuals history different malignancy ineligible except follow circumstance . Individuals history malignancy eligible diseasefree least 3 year deem investigator low risk recurrence malignancy . Individuals follow cancer eligible diagnose treat within past 5 year : cervical cancer situ , basal cell squamous cell carcinoma skin . 6 . HIVpositive individual combination antiretroviral therapy ineligible potential pharmacokinetic interaction temozolomide . In addition , individual increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake participant receive combination antiretroviral therapy indicate .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>